NVCT Latest Headlines

Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)

at www.tipranks.com (Fri, 24-Jul 11:36 AM)

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

at www.tipranks.com (Thu, 23-Jul 12:30 PM)

Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39

at www.tipranks.com (Thu, 23-Jul 11:25 AM)

Nuvectis Pharma Raises $100 Million to Accelerate Pipeline—NXP100, NXP900, and NXP200 in Focus

Market Chameleon (Tue, 30-Jun 7:05 AM)